glp·helper
glphelper.com/tirzepatide/massachusetts/springfield
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Springfield, MA

Verified Tirzepatide providers in Springfield, MA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Massachusetts
37 of 37 shown

Find a Tirzepatide provider in Massachusetts.

Every entry is checked against the NPI registry and the Massachusetts medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Massachusetts city · /tirzepatide/massachusetts/{city}
§ 03Getting Tirzepatide in Springfield
37 providers · Springfield, MA

How to get Tirzepatide in Springfield.

37 GLP-1 prescribers and 7 local resource types are on record for Springfield, plus 3 nearby towns in the directory.

Prescribers in Springfield
37 prescribers
37 GLP-1 prescribers in Springfield, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (12) and Internal Medicine (10). Any Massachusetts-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Worcester (40 providers), Cambridge (43 providers) and Boston (44 providers).
Around the prescription in Springfield
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 3 physiotherapists and 6 places to move are on record near Springfield.
Medicaid (weight loss)
Limited
As of April 2026, Massachusetts Medicaid covers GLP-1s for weight loss only in limited cases (BMI 30+, or 27+ with a related condition; narrowing in July 2026). Diabetes coverage is broader. Employer and private plans vary by plan.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Massachusetts’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Massachusetts

Diagnosed diabetes reaches 8.5% of adults in Massachusetts.

of Massachusetts adults have obesity
27%
diagnosed diabetes
8.5%

Age-adjusted estimates for Massachusetts, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossoral and sublingual GLP-1 options
§ 05Support around Tirzepatide in Springfield
6 gyms

The prescription is one part. Here is the rest, in Springfield.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Springfield, MA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

LA Fitness
GYM
4.2 on Google · 1162 reviews
1150 W Columbus Ave Ste 1
Website
Best Fitness Springfield
GYM
4.6 on Google · 876 reviews
1739 Allen St Unit 28A
Website
Planet Fitness
GYM
4.4 on Google · 695 reviews
510 Parker St
Website
Planet Fitness
GYM
4.4 on Google · 541 reviews
1183 Memorial Dr
Website
Century Fitness
GYM
4.6 on Google · 398 reviews
491 N Main St # 1
Website
Planet Fitness
GYM
4.4 on Google · 386 reviews
50 Holyoke St
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Spectacle Pond Recreation Area
REC CENTER
4.6 on Google · 317 reviews
2540 Boston Post Rd
Website
Club Fitness Enfield
FITNESS
4.2 on Google · 257 reviews
640 Enfield St
Website
Powerhouse Gym
FITNESS
4.4 on Google · 224 reviews
1452 Memorial Ave
Website
Powerhouse Gym Chicopee
FITNESS
4.3 on Google · 162 reviews
1501 Memorial Dr
Website
New England Functional Fitness
FITNESS
5.0 on Google · 125 reviews
168 Denslow Rd
Website
Next Fitness And Crossfit Catch
FITNESS
4.8 on Google · 99 reviews
470 Shoemaker Ln
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Massachusetts

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Massachusetts

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]